Pipeline — registered trials by phase
Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
— · Diabetes · Completed · est. 2011-12
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
— · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · Completed · est. 2008-06
Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics
— · Diabetes Mellitus · Completed · est. 2012-10
Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
— · Diabetes · Completed · est. 2012-02
G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator
— · Diabetes Mellitus · Completed · est. 2016-04
Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic Setting
— · Diabetes, Hyperglycemia · Completed · est. 2009-07
Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)
— · Diabetes · Not Yet Recruiting · est. 2030-05-01
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
— · Diabetes Mellitus, Type 2 · Completed · est. 2020-05-27
Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System
— · Diabetes Mellitus · Completed · est. 2021-08-09
Evaluation of Modified Adhesives With Dexcom G6 Sensor
— · Diabetes · Completed · est. 2021-03-16
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
— · Type 2 Diabetes · Active Not Recruiting · est. 2026-05-13
Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus
— · Diabetes Mellitus · Completed · est. 2013-01
Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia
— · Type 2 Diabetes on Insulin · Active Not Recruiting · est. 2026-11-02
Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring System
— · Diabetes Mellitus · Completed · est. 2017-07
Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm
— · Diabetes Mellitus · Completed · est. 2014-03
Glucose Risk Assessment in Employer Populations
— · Diabetes, Pre-diabetes, Glucose Intolerance · Completed · est. 2019-07-22
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System
— · Diabetes Mellitus · Completed · est. 2010-04
Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System
— · Diabetes Mellitus · Completed · est. 2012-12
Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
— · Diabetes Mellitus, Type 2 · Completed · est. 2021-01-04
Assessing Non-adjunctive CGM Safety at Home and in New Markets
— · Diabetes Mellitus · Completed · est. 2022-02-07
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
— · Type 1 Diabetes Mellitus · Completed · est. 2008-08
Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor
— · Type 2 Diabetes · Active Not Recruiting · est. 2026-01-16
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Dexcom is lead sponsor; 22 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-14Current report (material event)
- 8-K2026-09-10Current report (material event)
- 10-Q2026-07-30Quarterly report
- 8-K2026-07-30Current report (material event)
- 8-K2026-05-28Current report (material event)
- SD2026-05-28SD
- 8-K2026-05-15Current report (material event)
- 10-Q2026-04-30Quarterly report
- 8-K2026-04-30Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- ARS2026-04-15Annual report to holders
- DEFA14A2026-04-15DEFA14A
- DEF 14A2026-04-15Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 8-K2026-03-02Current report (material event)
- 8-K2026-02-26Current report (material event)
- 10-K2026-02-12Annual report
- 8-K2026-02-12Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-12-22Current report (material event)
- 10-Q2025-10-30Quarterly report
- 8-K2025-10-30Current report (material event)
- SCHEDULE 13G/A2025-10-30SCHEDULE 13G/A
- 8-K2025-10-27Current report (material event)
- 8-K2025-09-16Current report (material event)
- 10-Q2025-07-30Quarterly report
- 8-K2025-07-30Current report (material event)
- SD2025-05-29SD
- 8-K2025-05-13Current report (material event)
- 8-K/A2025-05-09Current report (amended)
- S-82025-05-09Employee stock plan
- 8-K2025-05-09Current report (material event)
- DEFA14A2025-05-02DEFA14A
- 8-K2025-05-02Current report (material event)
- 10-Q2025-05-01Quarterly report
- 8-K2025-05-01Current report (material event)
- SCHEDULE 13G/A2025-04-24SCHEDULE 13G/A
- ARS2025-03-27Annual report to holders
- DEFA14A2025-03-27DEFA14A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.